We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Maintenance metronomic chemotherapy for metastatic/recurrent nasopharyngeal carcinoma.
- Authors
Twu, Chih‐Wen; Lin, Po‐Ju; Tsou, Hsiao‐Hui; Liu, Yi‐Chun; Jiang, Rong‐San; Liang, Kai‐Li; Lin, Tian‐Yun; Wang, Wen‐Yi; Lin, Jin‐Ching
- Abstract
Background: We investigated the survival impact and toxicity of maintenance metronomic chemotherapy in patients with metastatic/recurrent nasopharyngeal carcinoma (met/rec NPC). Methods: Ninety‐eight patients with met/rec NPC were first salvaged by IV cisplatin‐based chemotherapy and showed nonprogression disease; then maintenance metronomic chemotherapy for at least 12 months was recommended. We analyzed the treatment outcome between patients who received (n = 51) and did not receive (n = 47) maintenance chemotherapy. Results: Baseline patient characteristics showed no significant differences between both arms. Median overall survival for patients with and without maintenance chemotherapy was 36.0 and 12.3 months, respectively (p < 0.0001). Similarly, median progression‐free survival was 24.7 and 7.3 months, respectively (p < 0.0001). Furthermore, toxicities during maintenance oral chemotherapy period were usually mild. Transient grade 3 leucopenia (9.8%), anemia (3.9%), thrombocytopenia (7.8%), and no grade 4 toxicity were observed. Conclusion: After IV salvage chemotherapy, maintenance oral metronomic chemotherapy significantly improved overall and progression‐free survivals while demonstrating low toxicity in patients with met/rec NPC.
- Subjects
NASOPHARYNX cancer; CANCER chemotherapy; OVERALL survival; PROGRESSION-free survival; TREATMENT effectiveness
- Publication
Head & Neck, 2022, Vol 44, Issue 6, p1453
- ISSN
1043-3074
- Publication type
Article
- DOI
10.1002/hed.27044